Chief Financial Officer · Akoya Biosciences, Inc. (AKYA)

Johnny Ek

FY2023 is the first fiscal year CompBrief holds for Johnny Ek as a named executive officer of Akoya Biosciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,309,744

Salary $313,889Stock awards $1,216,000

2nd of 3 named executive officers at Akoya Biosciences by FY2023 total.

3 named officers on file for Akoya Biosciences, FY2023

Johnny Ek’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Akoya Biosciences’s whole pay program stands against its peers

  • Akoya Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AKYA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2024 (DEF 14A).

Free

Get Johnny Ek’s full pay file as a PDF — free

More than this page: up to 10 years of Johnny’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Johnny Ek compensation by year

Akoya Biosciences Summary Compensation Table · the one fiscal year held
In US dollars, as Akoya Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$313,889
Bonus$0
Stock awards$1,216,000
Option awards$659,760
Non-equity incentive$118,269
Pension and deferred compensation$0
All other$1,826
Total$2,309,744

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akoya Biosciences, Inc. DEF 14A filed April 23, 2024, accession 0001104659-24-050208, and prior-year filings.

How this page was built: the Akoya Biosciences, Inc. filed document, accession 0001104659-24-050208. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU160,000$780,800—
Option160,000—$7.60

Per the Outstanding Equity Awards at Fiscal Year-End table in Akoya Biosciences, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Akoya Biosciences’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Brian McKelligonChief Executive Officer$2,919,599
Johnny Ek · this pageChief Financial Officer$2,309,744
Frederic PlaChief Operating Officer$1,211,385

The full Akoya Biosciences compensation record

free company brief

This page is one person within Akoya Biosciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akoya Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Johnny Ek's compensation dossier · One-time report. No refunds.